StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday.

Aptose Biosciences Stock Down 22.1 %

Shares of NASDAQ:APTO opened at $0.19 on Thursday. The company has a market cap of $3.44 million, a P/E ratio of -0.06 and a beta of 1.26. The business has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.61. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.91.

Institutional Trading of Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.